Company intelligence / Profile preview

Dendright

Brisbane, Queensland, Australiae-dendrite.com ↗

Ownership: Private
Development stage: Other

Overview

Dendright developed a nanoparticle-based immunotherapy platform (Curcusome) targeting autoimmune diseases. Its lead candidate, DEN-181, was designed to induce immune tolerance in rheumatoid arthritis by delivering disease-specific antigens and a VDR agonist. Early clinical trials showed some success, but the main program is currently suspended and there are no active late-stage programs.

Therapeutic areas: EndocrinologyImmunology
Modalities: NanoparticleBiologic
Industry: Biotech

Drug pipeline

2 assets

DEN-181

Unknown

1 more asset in the full pipeline.

Request access →

Partnerships

Janssen Biotech, Inc. (collaboration on rheumatoid arthritis immunotherapy development)

Beyond the preview

Go deeper on Dendright.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dendright.

Explore the full profile